Antiepileptic drug lamotrigine and its thirteen ammonium salt complexes (4a-4m) were synthesized and characterized by IR, elemental analysis, ¹H-NMR, and MS spectral methods. Many of the ammonium salts (4a-4m) were first reported. Furthermore, the crystal structure of compound 3 was determined by single crystal X-ray diffraction analysis. All these complexes were tested in vitro for their antibacterial activity (Bacillus subtilis, Staphylococcus aureus, Enterococus faecalis, Escherichia coli, Pseudomonas aeruginosa and Enterobacter cloacae). The results indicated that most of the complexes showed good antibacterial activity against Gram-positive (B. subtilis, S. aureus and S. faecalis), but showed mild, even inactive against Gram-negative bacterial strains.

A series of benzotriazole derivatives (compounds 1-27) were synthesized, and 24 (compounds 1-5, 9-27) of which were first reported. Their chemical structures were confirmed by means of 1H NMR, IR and elemental analyses, coupled with one selected single crystal structure (compound 1). All the compounds were assayed for antibacterial activities against three Gram positive bacterial strains (Bacillus subtilis, Staphylococcus aureus and Streptococcus faecalis) and three Gram negative bacterial strains (Escherichia coli, Pseudomonas aeruginosa and Enterobacter cloacae) by MTT method. Among the compounds tested, most of them exhibited potent antibacterial activity against the six bacterial strains. Most importantly, compound 3-benzotriazol-1-yl-1-(4-bromo-phenyl)-2-[1,2,4]triazol-1-ylpropan-1-one (19) showed the most favourable antibacterial activity against B. subtilis, S. aureus, S. faecalis, P. aeruginosa, E. coli and E. cloacae with MIC of 1.56 𝜇g/mL, 1.56 𝜇g/mL, 1.56 𝜇g/mL, 3.12 𝜇g/mL, 6.25 𝜇g/mL and 6.25 𝜇g/mL, respectively.